Skip to content

Study · Not a test of the peptide alone · 2021

4 results

Release of an Encapsulated Peptide from Carbon Nanotubes Driven by Electric Fields: A Molecular Dynamics Study.

Chen Q, Liang L, Zhang Z, Wang Q

ACS omega6 Oct 2021Cited by 4 (Europe PMC)

PMID34693169 (opens in a new tab)PMCIDPMC8529693 (opens in a new tab)DOI10.1021/acsomega.1c04436 (opens in a new tab)PepBankPUB-34693169
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01Computer modelNot a test of Thymosin alpha-1 aloneIn silicoOther

    In molecular dynamics simulations, external electric fields helped the peptide to overcome the potential well of carbon nanotubes during release.

    In plain wordsIn computer simulations, electric fields helped the peptide to leave carbon nanotubes.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableElectric-field assisted release from carbon nanotubes
    Study

    n: not reported in source

    Molecular dynamics simulation of carbon nanotubes
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    External electric fields can assist the peptide in overcoming the potential well during its release.
    2 context sentences
    Summary · context
    By performing molecular dynamics simulations, this work attempts to study the releasing process of encapsulated protein/peptide molecules from CNTs in the presence of uniform electric fields.
    Summary · context
    Zadaxin serves as a model for protein/peptide drugs.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02Computer modelNot a test of Thymosin alpha-1 aloneIn silicoOther

    In molecular dynamics simulations, successful release of the peptide from carbon nanotubes depended on pore width, pore length and net charge of the peptide.

    In plain wordsIn computer simulations, peptide release from carbon nanotubes depended on tube width, tube length and peptide charge.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableDependence of release on pore width, pore length and net charge
    Study

    n: not reported in source

    Molecular dynamics simulation of carbon nanotubes
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    It is found that successful release of the peptide depends on the pore width, the pore length, and the net charges on the peptide.
    2 context sentences
    Summary · context
    By performing molecular dynamics simulations, this work attempts to study the releasing process of encapsulated protein/peptide molecules from CNTs in the presence of uniform electric fields.
    Summary · context
    Zadaxin serves as a model for protein/peptide drugs.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03Computer modelNot a test of Thymosin alpha-1 aloneIn silicoOther

    In molecular dynamics simulations, the peptide was less likely to be released from nanotubes with a smaller pore diameter or a longer pore length.

    In plain wordsIn computer simulations, the peptide was less likely to leave narrower or longer nanotubes.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableRelease from narrow or long carbon nanotubes
    Study

    n: not reported in source

    Molecular dynamics simulation of carbon nanotubes
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    The peptide is less likely to be released either from CNTs with a smaller pore diameter due to a deeper potential well of the tubes or from CNTs with a longer pore length due to a broader and deeper potential well.
    2 context sentences
    Summary · context
    By performing molecular dynamics simulations, this work attempts to study the releasing process of encapsulated protein/peptide molecules from CNTs in the presence of uniform electric fields.
    Summary · context
    Zadaxin serves as a model for protein/peptide drugs.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04Computer modelNot a test of Thymosin alpha-1 aloneIn silicoOther

    In molecular dynamics simulations, peptides with more net charges were better suited to release driven by electric fields.

    In plain wordsIn computer simulations, peptides with more charge were better suited to electric-field release from nanotubes.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableRelease of peptides with more net charges
    Study

    n: not reported in source

    Molecular dynamics simulation of carbon nanotubes
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    Peptides with more net charges are ideal for the releasing process driven by electric fields.
    2 context sentences
    Summary · context
    By performing molecular dynamics simulations, this work attempts to study the releasing process of encapsulated protein/peptide molecules from CNTs in the presence of uniform electric fields.
    Summary · context
    Zadaxin serves as a model for protein/peptide drugs.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.